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During clinical trials, samples from Hungarian patients of different age 
groups were tested for antibodies against all 3 serotypes of poliovirus, a member of 
Picornaviridae family. During the virus neutralization serological test, blood sam-
ples were titrated using permanent virus concentration. Based on the cythopathic 
effect observed under a light microscope, the antibody level of the patient was as-
sessed. The 100 people examined were classifi ed into 5 groups based on age and 
type of original vaccine: I. Newborns, no vaccination given; II. Immunosuppressed 
patients; III. Born before 1986, received only OPV vaccine; IV. Born between 1992–
2005, received a combination of OPV and IPV vaccines; V. Born after 2006, re-
ceived only IPV vaccine. Results show that vaccination coverage meets all the 
criteria. None of the immunized persons was seronegative to all three polioviruses. 
Both IPV and OPV vaccines are effective against poliovirus. Blood samples from 
newborn babies with no immunization were also examined. Results show that most 
newborns have maternal antibodies in their blood. Results of group II show that im-
munosuppression does not have a negative infl uence on blood antibody levels against 
polioviruses. In spite of the low number of samples, our results show that serocon-
version after immunization in the Hungarian population is adequate. For more 
 accurate results about vaccination coverage in the population, further trials would be 
necessary.
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Introduction
Paraliticus poliomyelitis caused by polio virus was one of the most feared 
contagious diseases in the 20th century, and in some endemic countries it still 
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occurs. Poliovirus is a human enterovirus in Picornaviridae family [1]. The vi-
rion of polio is one of the smallest known virions with the size of 27–30 nm [2]. 
According to traditional taxonomy (valid until 2005), genus poliovirus was a 
separate group under its own name [3]. According to current taxonomy, all 3 se-
rotypes (PV1-3) are members of the group enterovirus C (EV-C) [4].
The virion is very resistant against detergents. It can preserve its virulence 
for days under +4 °C, and for years under –20 °C [5]. Formaldehyde and chloro 
derivates are effective disinfectants against the virus. The virions are sensitive to 
heat, dehydration and UV radiation [6]. Only humans are susceptible to the virus. 
Infected humans are the source of infection, whether the clinical course is symp-
tomatic or asymptomatic. Enteral spread is the most common way of infection, 
but nasal and throat secretions can also be contagious. Infected patients’ stool can 
also be infectious, therefore the main transmission path of the virus is feco-oral. 
Due to its resistance, the virion can preserve its virulence and can spread via 
contaminated hands, food, kitchen tools, sewage, etc. The latency period is 7–14 
days. Primer replication sites of the virus are the pharynx, the ileum of the intes-
tines and the regional lymphatic system [5]. More than 90% of the cases are 
asymptomatic. In 4–8% of cases the virus enters the blood-stream, and causes 
viraemia with fever, which passes with no complications in a few days. In a small 
percentage of the cases, the virus can enter the central nervous system (CNS) and 
cause mild nervous symptoms (non-paralytic poliomyelitis). In 0.01–2.0% of all 
cases, the virus can replicate in the motoric neurons of the CNS. Depending on 
the number and the location of these neurons, different forms of paralitic polio-
myelitis may develop [7].
In 1988, 125 endemic countries were registered and the estimated num-
ber of annual infections was 350,000. Due to polio eradication programmes, the 
number of endemic countries reduced to 3 (Afghanistan, Pakistan, Nigeria). 
Eradication in these countries has not been successful so far, and the virus is still 
circulating [8]. Virus transfer to non-endemic countries from endemic ones 
could be the cause of the 256 paralitic cases found in non-endemic regions in 
2013. The 160 cases registered in endemic areas indicates that changes in vaccine 
coverage can lead to epidemics [9].
In Syria, no cases have been registered between 1999 and 2013. Vaccine 
coverage among 5-year-olds was 83% in 2009 and 2010. Children did not receive 
vaccines during the civil war, and vaccine coverage reduced to 53% by 2013. 
A new polio epidemic appeared in the country: in 2013 35 cases were known, in 
2014 one infant developed paralitic poliomyelitis [10].
In 2014 (Until 17 December 2014), 333 new cases were registered globally. 
19 happened in non-endemic and 314 in endemic regions [9].
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The disease is incurable, only supportive therapy exists. Vaccination is the 
only option to achieve prevention. Two types of vaccines are used for immuni-
zation. One is the oral polio vaccine (OPV), which contains the virions alive. The 
other is inactivated polio vaccine (IPV). OPV (Sabin vaccine) is a trivalent vac-
cine containing living, attenuated strains from all 3 serotypes, and is received in 
drops. Two modes of seroconversion are known. First, vaccine induces immuno-
globulin-G (IgG) antibodies to be synthesized by lymphocytes, so they can neu-
tralize infective agents. Second, secretory IgA antibodies appear in intestinal 
mucosa and provides wider protection [11]. Inactivated polio vaccine (Salk vac-
cine), IPV is also trivalent and contains all 3 serotypes of the virus inactivated by 
formalin. IPV is received by injection and provides humoral prevention against 
polio, based only on IgG antibody synthesis [12].
According to World Health Organization’s (WHO) recommendation, the 
Sabin vaccine should have been altered globally with inactivated Salk vaccine by 
2010. Due to the mode of action of OPV, the living virus strains can replicate in 
the human body, and vaccine recipients can spread the virus by their stool. The 
only way to accomplish global polio eradication is to eliminate the circulation of 
all polio strains.
Current vaccination schedule in Hungary is regulated by the Act CLIV of 
1997 and the Decree 18/1998 (VI. 3) of the Ministry for Welfare on the Epide-
miological Protocols for Preventing Communicable Diseases and Outbreaks [13].
Oral polio vaccine was withdrawn in Hungary 1 April 2006. Since then, 
only IPV injection has been used for child immunization. According to the cur-
rent vaccination schedule, infants receive trivalent IPV 5 times, at the ages of 2, 
3, 4, 18 months and 6 years old [13].
Materials and Methods
Study group classifi cation and main objectives
During the laboratory trial, blood samples from Hungarian persons of dif-
ferent ages were tested for antibodies developed after immunization, for all 3 
serotypes of poliovirus with serological methods. The main goal was to achieve 
an insight of vaccination coverage amongst the Hungarian population and to 
compare the level of protection of two different types of vaccines.
All the persons tested were born in Hungary and were grouped based on 
age and the type of vaccine. OPV vaccine was introduced in 1959 in Hungary, 
and administered until 1992. In 2005, IPV vaccine was introduced. Between 
1992 and 1 November 2005, children received IPV and OPV vaccines combined. 
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In 2006, OPV vaccine was discontinued. Since then, only IPV vaccine is used for 
immunization.
Immunosuppressed patients were also tested for antibody levels. The main 
question was, if immunosuppression have any negative effect on developed anti-
body levels. Considering the introduction and withdrawal dates of the vaccines, 
and the ages of the examined persons, 5 different study groups were classifi ed:
I. Newborns, no vaccination given
II. Immunosuppressed patients
III. Born before 1986, received only OPV vaccine
IV. Born between 1992–2005, received a combination both of OPV and 
IPV vaccines
V. Born after 2006, received only IPV vaccine
Due to the altered dates of introduction of IPV in different geographical 
regions of Hungary in 1992 people born between 1986 and 1991 were not tested 
during this trial. Without knowing the exact history of immunization of the ex-
amined persons born within this period, it cannot be specifi ed which group they 
belong to.
Based on differentiation, the main objectives were:
• Is there any difference between antibody levels or seroconversion devel-
oped by different types of vaccination?
• Is there any difference between the half-life of the antibodies developed 
by the two different types of vaccination?
• Does aging have any effect on the serum antibody level?
• Can protective amounts of maternal antibodies travel through the pla-
centa providing protection for newborns until the fi rst dose of vaccine given them 
at 2 months age?
• Does immunosuppression have any negative effect on antibodies?
Virus neutralization serological test
During the trial, blood samples were tested with virus neutralization sero-
logical test [14].
The experiment was performed under BSL2 circumstances in biosafety 
cabinet and 96 well plates were used for the probe. Before the neutralization test, 
the blood samples were inactivated in 56 °C for 30 minutes.
Twenty-fi ve μl of RPMI medium (Rosewell Park Memorial Institute 
[ RPMI], Sigma-Aldrich) was measured into each well. Twenty-fi ve μl of the sam-
ples were added to the wells and diluted by twofold serial dilution. Each serum 
was tested in parallel.
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Twenty-fi ve μl virus-suspension was added to each well. The applied virus 
dilution was defi ned in advance as of 10–3. Vaccine-derived polio strains were 
used prescribed by WHO for the trial. Reference numbers were as follows: 
 Sabin 1 NIBSC (National Institute for Biological Standard and Control [NIBSC]) 
Reference Number 01/528, Sabin 2 NIBSC Reference Number 01/530, Sabin 3 
NIBSC Reference Number 01/532. Virus, serum and cell controls were added to 
each plates. Virus controls from all 3 serotypes of polio were added in the dilu-
tions 10–3, 10–4, 10–5, 10–6 respectively.
Seropositive serum with known titre values was used as serum control.
After adding the virus, the plates were incubated for 2 hours in 37 °C, 
whilst antibodies and antigens were conjugated.
After incubation, 100 μl polio-susceptible L20B mouse-derived transgenic 
cells were added to each well.
During the 5–7 days incubation period at 37 °C, the virus destroyed the 
cells in those wells, where antibodies could not neutralize the virus.
The cythopathic effect was examined every day under the light micro-
scope during the incubation period. Based on the cythopathic effect the antibody 
level of the patient was assessed.
Results
Results of the study are summarized in order of the examination groups.
I. Newborns, no vaccination given
Fifteen blood samples were tested in group I. Three infants had low anti-
body values (≤1:4 or ≤1:8). Most of the unvaccinated newborns had maternal 
 antibodies in their blood. One newborn was found to be seronegative to all three 
serotypes of polio virus, but none of the examined infants had high (1:256 or 
1:512) titre values. Relatively high antibody values against two serotypes were 
detected in case of three newborns. Against PV1 and PV3 the 1:4 was the most 
common titre value (27% and 47%), whilst against PV2 it was 1:256 (27%) (Fig. 1).
II. Immunosuppressed patients
Fifteen blood samples were tested in group II. Antibodies were detected in 
the sera of immunosuppressed patients. This indicates immunosuppression has 
no negative infl uence on serum antibody levels. None of the patients was seron-
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egative to all three serotypes. One person showed relatively low (≤1:4 or ≤1:8) 
titre values. Four patients had high antibody levels against all three serotypes. 
The most common titre values in case of PV1 serotype were 1:128 and 1:512 
(27%, 27%). Against PV2, 1:512 was the most common value (33%). The lowest 
value observed against PV3 was the titre 1:32 (33%) (Fig. 2).
III. Born before 1986, received only OPV vaccine
Twenty-one blood samples were tested in group III. None of the examined 
persons was seronegative to all three serotypes. One person had relatively low 
Figure 1. Distribution of antibody levels in group I. Horizontal axis shows antibody titre values, 
vertical axis shows the number of people who have the similar antibody level
Figure 2. Distribution of antibody levels in group II
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antibody values (≤1:4 or ≤1:8). Three showed high titres. Four people exhibited 
high antibody values against two serotypes of polio. In case of PV1 serotype, the 
most common titre value was 1:64 (33%), and 1:256 against PV2 (29%). Two 
groups of extreme values were found against PV3: six persons had ≤1:4 titre 
value (29 %) and fi ve showed 1:512 (24 %) (Fig. 3).
IV.  Born between 1992–2005, received a combination 
of OPV and IPV vaccines
Twenty-four blood samples were tested in group IV. None of the examined 
persons proved to be seronegative against any serotype. High titre values were 
Figure 3. Distribution of antibody levels in group III
Figure 4. Distribution of antibody levels in group IV
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detected in the group, the lowest antibody level was detected against PV3 with 
the titre 1:8. In case of PV1 serotype, the most common titre values were 1:32 
(25%) and 1:128 (25%). Against PV2 and PV3 1:512 titre value was the most com-
mon (50% and 33%) (Fig. 4).
V. Born after 2006, received only IPV vaccine
Twenty-three blood samples were tested for antibodies against polio virus 
in group V. The highest titre values were seen in this group. Most infants (87%) 
of the group did not receive the complete programme of vaccination (5 doses) 
against polio, the most common titre value against PV1 and PV2 was 1:512 (39% 
and 65%). None of the infants was seronegative to all 3 serotypes. Eight showed 
high (1:256 or 1:512) titre values (35%) against all the serotypes. The most com-
mon antibody level against PV3 was 1:128 (39%) (Fig. 5).
Figure 5. Distribution of antibody levels in group V
Discussion
During the study, 100 blood samples were tested for antibodies against all 
three serotypes of polio virus. Figure 6 shows the distribution of the antibody 
levels amongst the tested groups. In conclusion, the vaccination coverage in Hun-
gary exceeds the level required to prevent infections. Antibody titres are gener-
ally high, and none of the immunized group was seronegative to all three polio-
viruses.
Comparing the results of groups III, IV and V, it is proven that both IPV 
and OPV are effective against polio virus. Newly immunized infants in group V 
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Figure 6. Vaccination coverage in Hungarian population: 
Distribution of the antibody levels against 3 different virus serotypes among the 100 examined patients
showed the highest titre values. In group III antibody levels were lower with 
higher deviation value. As the level of neutralizing antibodies reduce in time, 
those newly immunized children who have higher titre values now, than earlier 
vaccinated adults, need to be monitored to complete the survey. Comparing the 
result of groups III and IV, it is evident that antibody levels are higher in group IV.
American scientists performed a similar clinical test amongst Guatemalan 
infants in 2007. The goal of the trial was to compare the effi cacy of the IPV and 
OPV vaccines. Children were classifi ed into three groups: IPV receivers only, 
OPV receivers only and those who received a combination of IPV and OPV vac-
cines. Results show that seropositivity against all 3 serotypes was 100% after 
three doses of IPV vaccination, while after OPV vaccination seropositivity was 
99%, 100% and 97% against PV1, PV2 and PV3, respectively. IPV vaccinated 
infants showed higher titre values than OPV receivers, but had the same values as 
those who both IPV and OPV receivers [15].
It is important to highlight, that the highest antibody levels were experi-
enced against PV2 serotype in all fi ve groups (Fig. 6). The lowest levels were 
observed against PV3.
Highest deviation values are in groups I, II and III, the lowest are in groups 
IV and V. Examining the dilution rates in group V the average deviations were 
between 1 and 1.7. With the exception of group V, the highest deviation values 
were experienced against PV3 serotype.
An Italian study published in 2006 stated, newly immunized minors 
(1–17-year-old) showed much higher antibody titre values than formerly vacci-
nated elders (65–100-year-old). No seronegativity was experienced amongst the 
vaccinated population [16].
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Results of group I show, that maternal IgG antibodies can travel through 
the placenta and give the foetus a passive protection. Half-life of maternal anti-
bodies in newborns’ blood is 28 days. The protective period depends on the post-
natal antibody level passed onto the newborn [5].
Blood samples from two newborn infants were collected on the day of 
birth. In the fi rst newborn, the results against PV1, PV2 and PV3 serotypes were 
1:4, 1:64 and ≤1:4. The second newborn’s titre values were 1:64, 1:256 and 1:256.
Tested immunosuppressed patients show no deterioration in levels of pro-
tection. Patients in group II had average or high titre values, but results showed 
relatively high deviation.
The results cannot be considered as representative because of the low num-
ber in the sample groups. However, the study shows that seroconversion after 
vaccination in the Hungarian population is adequate. To achieve accurate results 
about vaccination coverage in the population, further trials would be necessary.
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